Genentech’s Fenebrutinib Yields Positive Results in Phase III MS Trial
Genentech’s oral BTK inhibitor fenebrutinib met its primary endpoint in the Phase III FENtrepid trial for primary progressive multiple sclerosis, showing non‑inferiority to Ocrevus and a 12% risk reduction in confirmed disability progression. The drug also delivered a 26% lower risk of worsening upper‑limb function on the nine‑hole peg test and a 22% reduction on a composite functional disability measure. Safety was comparable, with modest liver enzyme elevations but no severe injury. These results position fenebrutinib as the first potential new therapy for PPMS in over a decade.
Anti-Aging Gene Therapy in Alzheimer’s and ALS with Klotho Neurosciences’ Dr. Joseph Sinkule — Episode 243
The Xtalks Life Science Podcast featured Joseph Sinkule, CEO of Klotho Neurosciences, discussing the company’s secreted α‑Klotho gene therapy platform aimed at age‑related neurodegenerative diseases such as Alzheimer’s, ALS and Parkinson’s. Klotho leverages a patented anti‑aging gene to develop cell‑ and...
